His main research concerns Prostate cancer, Cancer, Internal medicine, Prostate and Oncology. Freddie C. Hamdy is involved in the study of Prostate cancer that focuses on Prostate-specific antigen in particular. His research on Prostate-specific antigen also deals with topics like
His Cancer study incorporates themes from Bioinformatics and Pathology. His Internal medicine research incorporates elements of Endocrinology and DNA methylation. His work carried out in the field of Prostate brings together such families of science as Cancer research and Adenocarcinoma.
Freddie C. Hamdy mainly investigates Prostate cancer, Internal medicine, Oncology, Cancer and Prostate. His research in Prostate cancer is mostly concerned with Prostate-specific antigen. His Internal medicine study frequently links to adjacent areas such as Endocrinology.
His studies deal with areas such as Bladder cancer, Prostatectomy, PCA3, Prostate cancer screening and Stage as well as Oncology. His research in Cancer is mostly concerned with Breast cancer. His Prostate research is multidisciplinary, relying on both Randomized controlled trial and Adenocarcinoma.
His primary areas of study are Prostate cancer, Internal medicine, Oncology, Prostate and Cancer. His Prostate cancer research incorporates themes from Cancer research, Randomized controlled trial and Hazard ratio. Internal medicine is closely attributed to Gynecology in his research.
Freddie C. Hamdy combines subjects such as Genetic predisposition, Proportional hazards model, Genotype, Health equity and Prostate cancer risk with his study of Oncology. The concepts of his Prostate study are interwoven with issues in Radiology and Incidence. Freddie C. Hamdy interconnects Lung cancer and Epidemiology in the investigation of issues within Cancer.
Prostate cancer, Internal medicine, Oncology, Prostate-specific antigen and Prostate are his primary areas of study. His Prostate cancer research includes elements of Cancer research, Genome-wide association study, Surgery and Cohort. His Oncology study combines topics from a wide range of disciplines, such as Percentile, Germline mutation, Genetic predisposition and Genotype.
His Prostate-specific antigen research integrates issues from Meta-analysis, Biopsy, Cohort study and Mass screening. The Prostate study combines topics in areas such as Sperm, Endocrinology, Clinical trial and Tumor microenvironment. Hazard ratio is closely connected to Gynecology in his research, which is encompassed under the umbrella topic of Cancer.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer
Freddie C. Hamdy;Jenny L. Donovan;J. Athene Lane;Malcolm Mason.
(2016)
Pan-cancer analysis of whole genomes
Peter J. Campbell;Gad Getz;Jan O. Korbel;Joshua M. Stuart.
(2020)
Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer
Donovan Jl;Hamdy Fc;Lane Ja;Mason M.
(2016)
Multiple newly identified loci associated with prostate cancer susceptibility.
Rosalind A Eeles;Rosalind A Eeles;Zsofia Kote-Jarai;Graham G Giles;Graham G Giles;Ali Amin Al Olama.
Nature Genetics (2008)
Changes in circulating microRNA levels associated with prostate cancer
R J Bryant;T Pawlowski;J W F Catto;G Marsden.
British Journal of Cancer (2012)
Quality improvement report: Improving design and conduct of randomised trials by embedding them in qualitative research: ProtecT (prostate testing for cancer and treatment) study. Commentary: presenting unbiased information to patients can be difficult.
Jenny Donovan;Nicola Mills;Monica Smith;Lucy Brindle.
BMJ (2002)
Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array
Rosalind A. Eeles;Ali Amin Al Olama;Sara Benlloch;Edward J. Saunders.
Nature Genetics (2013)
Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients.
Jean Christophe Carraro;Jean Pierre Raynaud;Gary G Koch;Geoffrey D. Chisholm.
The Prostate (1996)
Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci
Fredrick R. Schumacher;Ali Amin Al Olama;Sonja I. Berndt;Sara Benlloch.
Nature Genetics (2018)
MicroRNA in prostate, bladder, and kidney cancer: a systematic review.
James W F Catto;Antonio Alcaraz;Anders S. Bjartell;Ralph W deVere White.
European Urology (2011)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
University of Cambridge
University of Bristol
University of Bristol
Institute of Cancer Research
University of Sheffield
University of Manchester
University of Melbourne
Institute of Cancer Research
University of Utah
Fred Hutchinson Cancer Research Center
University of Melbourne
Ludwig-Maximilians-Universität München
University of Cambridge
Northwestern Polytechnical University
Nankai University
Aalto University
Hunan University
University of Cambridge
Dalhousie University
Rice University
University of Genoa
Lund University
Clark University
University of Kent
Tohoku University
Cardiff University